Menu
Search
|

Menu

Close
X

Geron Corp GERN.OQ (NASDAQ Stock Exchange Global Select Market)

1.56 USD
-- (--)
As of Feb 19
chart
Previous Close 1.56
Open --
Volume --
3m Avg Volume 794,743
Today’s High --
Today’s Low --
52 Week High 6.99
52 Week Low 0.95
Shares Outstanding (mil) 186.35
Market Capitalization (mil) 290.70
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
1
FY16
6
EPS (USD)
FY18
-0.115
FY17
-0.175
FY16
-0.186
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
36.18
Price to Sales (TTM)
vs sector
329.60
10.03
Price to Book (MRQ)
vs sector
1.55
4.56
Price to Cash Flow (TTM)
vs sector
--
26.61
Total Debt to Equity (MRQ)
vs sector
0.00
16.56
LT Debt to Equity (MRQ)
vs sector
0.00
13.03
Return on Investment (TTM)
vs sector
-18.61
12.67
Return on Equity (TTM)
vs sector
-18.61
13.70

EXECUTIVE LEADERSHIP

John Scarlett
Chairman of the Board, President, Chief Executive Officer, Since 2018
Salary: $644,000.00
Bonus: --
Olivia Bloom
Chief Financial Officer, Executive Vice President - Finance, Treasurer, Since 2014
Salary: $410,000.00
Bonus: --
Andrew Grethlein
Principal Operating Officer, Executive Vice President, Since 2019
Salary: $416,200.00
Bonus: --
Israel Gutierrez
Vice President, Pharmacovigilance and Drug Safety, Since 2019
Salary: --
Bonus: --
Melissa Kelly Behrs
Chief Business Officer, Since 2019
Salary: $386,500.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

149 Commonwealth Dr Ste 2070
MENLO PARK   CA   94025-1133

Phone: +1650.4737700

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.

SPONSORED STORIES